Apogee Therapeutics, Inc.
APGE
Rang in Aktien
#2351
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aktienkurs
$135.07
Zuletzt synchronisiert: 2026-09-04
Marktkapitalisierung
$8.36B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
137.21%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategorie
Healthcare
P/B-Verhältnis für Apogee Therapeutics, Inc. (APGE)
P/B-Verhältnis zum October 2026 TTM: 8.53
Laut den neuesten Finanzberichten und dem Aktienkurs von Apogee Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 8.53. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 3.73.
P/B-Verlauf für Apogee Therapeutics, Inc. von 2022 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
